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NeuroblastomaHigh-risk neuroblastoma (NB) is characterized by the development of chemoresistance, and bortezomib (BTZ), a
selective inhibitor of proteasome, has been proposed in order to overcome drug resistance. Considering the in-
volvement of the nuclear factor-erythroid-derived 2-like 2 (Nrf2) and heme oxygenase-1 (HO-1) in the antiox-
idant and detoxifying ability of cancer cells, in this study we have investigated their role in differently aggressive
NB cell lines treated with BTZ, focusing on the modulation of HO-1 to improve sensitivity to therapy. We have
shown that MYCN ampliﬁed HTLA-230 cells were slightly sensitive to BTZ treatment, due to the activation of
Nrf2 that led to an impressive up-regulation of HO-1. BTZ-treated HTLA-230 cells down-regulated p53 and up-
regulated p21, favoring cell survival. The inhibition of HO-1 activity obtained by Zinc (II) protoprophyrin IX
(ZnPPIX) was able to signiﬁcantly increase the pro-apoptotic effect of BTZ in a p53- and p21-independent way.
However, MYCN non-ampliﬁed SH-SY5Y cells showed a greater sensitivity to BTZ in relation to their inability
to up-regulate HO-1. Therefore, we have shown that HO-1 inhibition improves the sensitivity of aggressive NB
to proteasome inhibition-based therapy, suggesting that HO-1 up-regulation can be used as a marker of
chemoresistance in NB. These results open up a new scenario in developing a combined therapy to overcome
chemoresistance in high-risk neuroblastoma.
© 2013 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
Neuroblastoma (NB) is the most common extra-cranial solid tumor
in childhood. It accounts for 8–10% of all pediatric cancers and 15% of
childhood cancer mortality [1]. One of the clinical hallmarks of neuro-
blastoma is heterogeneity, varying from the highly aggressive
chemoresistant disease to the spontaneous regression in infants [2]. De-
spite advances in the treatment of other childhood tumors, high-risk
neuroblastoma remains one of the most difﬁcult cancers to cure with
long-term survival still less than 40%. A typical feature of high-risk






. Open access under CC BY-NC-ND license.neuroblastoma, associated with rapid tumor progression, chemo-
resistance and poor prognosis [3].
The availability of antioxidants is recognized as one of the critical
mechanisms able to provide cancer cells with resistance to anticancer
therapies [4]. In drug resistance, nuclear factor-erythroid-derived 2-
like 2 (Nrf2) is reported to play a key role [5]. Nrf2 is activated in re-
sponse to electrophylic stimuli and oxidative stress and regulates the
expression of many antioxidant and detoxifying genes involved in the
development of chemoresistance [6]. Among Nrf2 target genes, heme
oxygenase-1 (HO-1) is considered a master regulator of antioxidant re-
sponse. Heme oxygenase is the ﬁrst and rate-limiting enzyme in the
degradation of heme into biliverdin, carbon monoxide (CO), and free
iron [7]. HO-1, the inducible form of the HO system, is a 32-kDa stress
protein and is present at low levels in most mammalian tissues [8]. Its
expression is induced by a wide variety of stress stimuli, including its
substrate, heavy metals, UV irradiation, reactive oxygen species (ROS),
nitric oxide, and inﬂammatory cytokines [9–11]. HO-1 and itsmetabolic
products are involved in the maintenance of cellular homeostasis and
play a key role in the adaptive response to cellular stress [12]. Recent ex-
perimental evidence has shown the involvement of HO-1 in cancer cell
biology, with a dual role. On one hand, HO-1 protects healthy cells from
transformation into neoplastic cells by counteracting ROS mediated
614 A.L. Furfaro et al. / Biochimica et Biophysica Acta 1842 (2014) 613–622carcinogenesis. On the other hand, HO-1 protects cancer cells, improv-
ing their survival and their resistance to anticancer treatment [13].
High levels of HO-1 have been observed in various human solid tumors
(e.g. renal, prostatic and pancreatic) [14–16]. Moreover, HO-1 expres-
sion in tumor cells can be further increased by anticancer treatments
(chemo-, radio-, and photodynamic therapy) [16] and it has been hy-
pothesized that HO-1 and its products may have an important role in
the development of a resistant phenotype [17,18].
Among the new therapeutic strategies designed to overcome cancer
cell resistance, the use of proteasome inhibitors has been proposed
[19,20].
Bortezomib (BTZ), a selective and reversible inhibitor of the 26S pro-
teasome, the major intracellular pathway of protein degradation, has
shown impressive clinical results in anticancer therapeutic approaches.
BTZ was approved in 2004 by the US FDA for the treatment of multiple
myeloma [21]. Recent experimental evidence has shown that BTZ treat-
ment is able to overcome cancer cell resistance in different solid tumors
[22].
In this study we have investigated the effects of bortezomib treat-
ment on neuroblastoma cell lines. We used two NB cell lines: SH-
SY5Y, MYCN non-ampliﬁed, and HTLA-230, MYCN ampliﬁed, in order
to mimic two differently aggressive conditions and to compare their
sensitivity to bortezomib. In particular, Nrf2/HO-1 pathway has been
studied in both cell lines, focusing on the effect of HO-1 modulation to
improve BTZ efﬁcacy.2. Materials and methods
2.1. Cell culture and treatments
MYCN non-ampliﬁed SH-SY5Y cells and MYCN ampliﬁed, stage IV,
HTLA-230 human neuroblastoma cells were obtained from Prof. V.
Pistoia (G. Gaslini Institute, Genoa, Italy). Both cell lines were main-
tained in RPMI 1640 medium (Euroclone, Milan, Italy) supplemented
with 10% FBS (Euroclone), 2 mM glutamine (Sigma-Aldrich, Milan,
Italy), 1% penicillin/streptomycin (Sigma-Aldrich) and 1% amphotericin B
(Sigma-Aldrich), at 37 °C in a 5% CO2 humid atmosphere and sub-
cultured every 4 days at 1:5.
Both cell lines were treated for 24 h with 5, 10, 20 and 40 nM
bortezomib (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Some
samples were co-treated with 2.5 μM Zinc (II) protoporphyrin IX
(Sigma-Aldrich).2.2. MTT assay
Cell viability was evaluated by using 3-(4,5-dimethyl-thiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT, Sigma-Aldrich) assay. Cells
were plated in 96-well plates and after 24 h of bortezomib treatment,
incubated with 5 μg/ml MTT for 3 h at 37 °C. Insoluble formazan salts
were dissolved in DMSO. The absorbance at 570 nm was measured
with a spectrophotometric plate reader (EL-808 BIO-TEK Instruments
Inc.). Mean values from each treatmentwere calculated as a percentage
relative to the untreated control cells.2.3. Detection of cells death by FACS analysis
After treatment, cells were stained with Annexin V-FITC and
Propidium Iodide according to the manufacturer's instructions
(BioVision, Mountain View, CA, USA). Stained samples were analyzed
by ﬂow cytometry using a FACSCanto II ﬂow cytometer (Becton Dickin-
son Italia, BD, Milan, Italy) equipped by FacsDiva software (BD). At least
10,000 events were analyzed. Each experiment was performed three
times.2.4. Cell proliferation assay
Cell proliferation was evaluated by staining cells with carboxyl ﬂuo-
rescein succinimidyl ester (CFDA-SE, Invitrogen,Milan, Italy), a lipophil-
ic dye that reactswith amino groups on peptides and proteins forming a
stable amide bond, and detection by ﬂow cytometry analysis [18,23].
Cells were seeded in six-well plates, washed and incubated with 5 μM
CFDA-SE in 10 mM PBS in the dark at 37 °C in 5% CO2 for 5 min. At
the end of incubation, the cells were washed three times with 10 mM
PBS supplemented with 1% FBS. Then, the samples were exposed to
the treatments described in Section 2.1. After 24 h cells were washed
and scraped-off in PBS and the intensity of CFDA-SE ﬂuorescence was
evaluated by ﬂow cytometry. The proliferation of CFDA-SE-labeled
cells was estimated by the progressive halving of cellular ﬂuorescence
as every cell division was completed. Samples were analyzed using a
FACSCanto II ﬂow cytometer and FacsDiva software (BD). The ﬂow cy-
tometry data ﬁles were analyzed using the ProliferationWizardmodule
of theModFit LT 3.2 software (Verity Software House Inc., Topsham,ME,
USA). Each experiment was performed three times.
2.5. RNA extraction and RT-PCR
Total RNA was extracted using TRIZOL reagent (Invitrogen) accord-
ing to themanufacturer's instructions andwas then reverse transcribed
into cDNA by random hexamer primers and SuperScript™ II Reverse
Transcriptase (Invitrogen). Ampliﬁcation of cDNA by polymerase
chain reaction was performed using Platinum Taq DNA Polymerase
(Invitrogen) and speciﬁc primers for human GCLC, GCLM, HO-1,
NQO1, x-CT, p21 and MYCN. Ribosomal 18S expression was used as
the housekeeping gene. Primer sequences used (Tib Mol Biol, Genoa,
Italy) were: GCLC Fw 5′ ATG GAG GTG CAA TTA ACA GAC 3′; GCLC Rv
5′ ACT GCA TTG CCA CCT TTG CA 3′ (206 bp); GCLM Fw 5′ CCA GAT
GTC TTG GAA TGC 3′; GCLM Rv 5′ TGC AGT CAA ATC TGG TGG 3′
(408 bp); HO-1 Fw 5′ GCT CAA CAT CCA GCT CTT TGA GG 3′; HO-1 Rv
5′ GAC AAA GTT CAT GGC CCT GGG A 3′ (284 bp); NQO1 Fw 5′ CAC
TGA TCG TAC TGG CTC A 3′; NQO1 Rv 5′ GCA GAA TGC CAC TCT GAA T
3′ (516 bp); x-CT Fw 5′ CGT CCT TTC AAG GTG CCA CTG 3′; x-CT Rv 5′
TGT CTC CCC TTG GGC AGA TTG 3′ (295 bp); p21 Fw 5′ GTC CAG CGA
CCT TCC TCA TCC A 3′; p21 Rv 5′ CCA TAG CCT CTA CTG CCA CCA TC 3′
(108 bp);MYCN Fw 5′ CCT GAG CGA TTC AGA TGA TG 3′; MYCN Rv 5′
GGC TCA AGC TCT TAG CCT TT 3′ (337 bp); 18s Fw 5′ GGG GCC CGA
AGC GTT TAC T 3′; 18s Rv 5′ GGT CGG AAC TAC GAC GGT ATC 3′
(296 bp). PCR products were separated by electrophoresis on 2% aga-
rose gel pre-stained with ethidium bromide, visualized under UV light
and quantiﬁed by densitometric analysis by using a speciﬁc software
(GelDoc, BioRad, Milan, Italy).
2.6. Total protein extraction
Total protein extraction was performed using RIPA buffer as previ-
ously described [18].
2.7. Subcellular fractioning
Cytosolic and nuclear protein extraction was performed by using
Nuclear Extract Kit (ActiveMotif, Belgium) following themanufacturer's
instruction. Protein concentration of each subcellular fraction was mea-
sured using the BCA test (Pierce, Thermo Fisher Scientiﬁc, Rockford,
USA).
2.8. Western Blot
Proteins were denatured in Laemmli buffer and then subjected
to 10% or Any-kD SDS-polyacrylamide gel electrophoresis 200 V
for 50 min (Mini Protean TGX Gel, Bio-Rad, Milan, Italy), followed
by electroblotting (100 V for 50 min) on PVDF membrane (Pierce).
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Santa Cruz Biotech.), anti Keap-1(H436, Cell Signaling Technology,
Boston, MA, USA), anti p53 (sc-126, Santa Cruz Biotech.), anti HO-1
(ab-13248, Abcam Cambridge, UK), anti Ubiquitin (sc-8017, Santa
Cruz Biotech.), anti p21(sc-6246, Santa Cruz Biotech.) and anti N-myc
(OP13,OP13L Calbiochem, Merck Millipore, Italy).
After incubation with secondary antibody, the speciﬁc bands were
detected bymeans of an enhanced chemiluminescence system (Pierce).
The membranes were stripped using Re-blot plus solution (Chemicon
International, CA, USA) and re-probed with anti tubulin (ab56676,
Abcam) and anti laminin B1 (ab20396, Abcam). Developed ﬁlms were
analyzed using a speciﬁc software (GelDoc, Bio-Rad, Milan, Italy).Fig. 1.Bortezomib treatment decreases cell viability and slows downproliferation rate. (A) Cells
graph shows themean values of three independent experiments (means ± SE); *p b 0.001 and
trations of BTZ and the apoptotic rate (% of Annexin V positive cells) was assessed by AnnexinV
dent experiments (means ± SE); *p b 0.01 vs untreated cells. (C, D) Cells were stained with C
graphs show the mean values of three independent experiments (means ± SE). Bar color mea
tion; magenta = fourth generation; cyan = ﬁfth generation.2.9. Electrophoretic mobility shift assay
ARE oligonucleotide was synthesized by TIB Molbiol using a com-
monly used sequence (5′-Tgg ggA ACC TgT gCT gAg TCA CTg gAg) [24].
The oligonucleotide was labeled using [γ-32P]ATP (PerkinElmer,
USA) and T4 polynucleotide kinase (New England BioLabs, UK) and pu-
riﬁed onQuick Spin Columns (G-25 Sephadex comumns) (Roche,Milan,
Italy).
Equal amounts (2 μg) of nuclear extract proteinswere added to a re-
action mixture containing 20 μg of BSA, 2 μg of poly (dI-dC) (Pierce),
2 μl of buffer A (20 mM HEPES pH 7.9, 20% glycerol, 100 mM KCl,
0.5 mM EDTA, 0.25% Nonidet P-40, 2 mM DTT, and 0.1% PMSF), 4 μl ofwere treatedwith 20 and40 nMBTZ for 24 h and viabilitywas analyzed byMTT assay. The
**p b 0.0001 vs respective untreated cells. (B) Cells were treatedwith increasing concen-
/PI staining followed by FACS analysis. The graph shows themean values of three indepen-
FDA-SE, treated with increasing concentration of BTZ for 24 h and analyzed by FACS. The
nings: blue = parental generation; orange = second generation; green = third genera-
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0.1% PMSF), 5 mMMgCl2 and 20.000 cpm of a 32P-labeled oligonucle-
otide in a ﬁnal volume of 20 μl.
After 20 min at room temperature, the reaction products were sep-
arated on a 4% non-denaturing polyacrylamide gel. Radioactivity of
dried gel was detected by exposure to Kodak XAR ﬁlms, and the bands
were analyzed by densitometry.
2.10. Statistical analysis
The data are presented as amean ± standard error fromat least three
independent experiments. The statistical signiﬁcance was evaluated by
one-way ANOVA followed by Dunnet post-test, or by t-test to compare
two groups, using GraphPad Prism software (San Diego, CA, USA).
3. Results
3.1. Analysis of cell viability and proliferation after exposure to BTZ
As shown in Fig. 1A, SH-SY5Y cell viability decreased by about 55%
and 65% after 24 h of 20 and 40 nM BTZ treatments respectively, in
comparison to the vehicle control as revealed by MTT assay. However,
HTLA-230 cells treated with the same BTZ concentrations for the sameFig. 2. Bortezomib treatmentmainly increases HO-1 among the Nrf2-dependent genes. (A) RT-P
total RNA extracted from SH-SY5Y and HTLA-230 cell lines treatedwith to 5–40 nMBTZ for 24
were normalized to 18S expression. The bar graphs show themean values of three independent
representative of three independent experiments.experimental time showed a decrease in viability of about 30% in com-
parison to the vehicle controls.
Cytoﬂuorimetric analysis showed that 24 h treatment with 10, 20
and 40 nM BTZ induced a dose-dependent increase in Annexin V-
positive SH-SY5Y cells of about 12%, 19% and 27% respectively. However,
the number of Annexin V-positive HTLA-230 cells increased by 18% at
20nM BTZ treatment with no further signiﬁcant increase at 40 nM
(Fig. 1B).
The analysis of the proliferation rate showed that both cell lines,
when untreated, proliferated strongly and after 24 h were mainly in
second and third generation (as illustrated by the red and green bars re-
spectively in Fig. 1C and D). However, the treatment with 5 nM BTZ in-
creased the number of SH-SY5Y cells in the second generationwhile the
same dose had no effects on HTLA-230, showing that SH-SY5Y were
more sensitive to the cytostatic effect of BTZ than the HTLA-230 cells.
Furthermore,WB analysis showed a dose-dependent increase of protein
ubiquitination pattern in both cell lines treatedwith BTZ, conﬁrming the
efﬁcacy of proteasome inhibition (data not shown).
3.2. Analysis of Nrf2-dependent genes in BTZ-treated neuroblastoma cells
In order to evaluate the antioxidant and/or detoxifying cell response,
we analyzed the Nrf2 target genes. As shown in Fig. 2, in neither cellCR analysis of Nrf2-dependent genes (GCLC, GCLM, NQO1, x-CT, HO-1) was performed on
h. PCR products were separated by electrophoresis and the relative intensities of the bands
experiments (means ± SE); * p b 0.05 and **p b 0.01 vs untreated cells. (B) The bands are
617A.L. Furfaro et al. / Biochimica et Biophysica Acta 1842 (2014) 613–622lines, after 24 h BTZ treatment (5–40 nM), were changes observed, ei-
ther in the mRNA expression of heavy and light subunits of glutamyl
cysteine ligase (GCLC, GCLM) or in the NQO1 expression. TheFig. 3.Nrf2 protein level is increased in both cell lines treatedwith bortezomib but its ability to b
total cell lysates using a standardWB technique, checking tubulin expression as loading control
control; (D) nuclear protein ability to bind the DNA ARE consensus sequence was evaluated usin
graphs show the mean values of three independent experiments. *p b 0.01 and **p b 0.001 vstransporter of cysteine, x-CT,was up-regulated in both cell lines, regard-
less of the BTZ concentration used (Fig. 2). However, BTZ treatment in
SH-SY5Y induced HO-1 at 5 and 10 nM, by about 4-fold in comparisonind to DNA is different. Nrf2 (A), Keap-1 (B) andHO-1 (E) protein levelswere evaluated in
. (C) Nrf2 levels of nuclear fractions have been analyzed byWB using laminin B1 as loading
g EMSA assay. All the blots reported are from one representative experiment of three. The
respective untreated samples.
618 A.L. Furfaro et al. / Biochimica et Biophysica Acta 1842 (2014) 613–622to untreated cells, whereas, in HTLA-230 cells, HO-1 was strongly up-
regulated up to 20 fold at the highest doses of BTZ (20 and 40 nM) in
comparison to the control samples (Fig. 2).
3.3. Analysis of Nrf2 and HO-1 protein level in neuroblastoma cells exposed
to BTZ
Nrf2 total protein expression progressively increased in HTLA-230
cells exposed to increasing concentrations of BTZ (up to 6 fold at 20 nM
BTZ) while SH-SY5Y cells showed a dose-independent increase of about
2.5 fold already at the lowest doses used (5 nM, Fig. 3A). In addition, a
progressive decrease of Keap-1 protein level in both cell lines was ob-
served (Fig. 3B). However, the analysis of nuclear fractions showed a
marked dose-dependent increase of Nrf2 protein in HTLA-230 cells treat-
edwith BTZwhile no signiﬁcant enhancement of Nrf2 levels in the nucle-
us was observed in SH-SY5Y cells exposed to the same treatment
(Fig. 3C). Furthermore, electrophoretic mobility shift assay (EMSA)
showed that the binding of nuclear proteins to the antioxidant responsive
element (ARE) consensus sequence was increased in HTLA-230 cells ex-
posed both to the lowest and the highest doses of BTZ while the same
treatments were not able tomodify the ability of SH-SY5Y-derived nucle-
ar proteins to bind to the DNA ARE sequence (Fig. 3D). Finally, HO-1 pro-
tein level was markedly increased by BTZ in a dose-dependent way in
HTLA-230 (up to +350% vs untreated cells at 40 nM) while a signiﬁcant
up-regulation (+70% vs untreated cells) was observed only at the lowest
doses used in SH-SY5Y (Fig. 3E). This was in agreementwith themodula-
tion of mRNA expression shown in Fig. 2.
3.4. Effect of HO-1 inhibition on BTZ-treated cell viability and proliferation
In order to check if HO-1 inhibition could increase cytostatic and/or
cytotoxic effect of BTZ, both cell lines were treated with 2.5 μM ZnPPIX,
either alone or in combination with 10 nM BTZ and the apoptotic rate
was evaluated. As shown in Fig. 4, the inhibition of HO-1 activity in-
creased the number of apoptotic HTLA-230 cells by 26% in comparison
to untreated cells and by 18% in comparison to cells treated with BTZ
alone. However, in SH-SY5Y cells, HO-1 activity inhibition did not inﬂu-
ence the apoptotic effect of BTZ.
However, ZnPPIX did not change the proliferation slowdown in-
duced by BTZ in either cell lines (data not shown).
3.5. Effect of HO-1 inhibition on p53 levels in neuroblastoma cells exposed
to BTZ
WB analysis of p53 expression level revealed a dose-dependent de-
crease from a 50% to a70% reduction vs control in HTLA-230 cells ex-
posed to 10–40 nM BTZ while the same BTZ treatment gradually
increased the p53 expression level in SH-SY5Y cells (Fig. 5A). However,
HO-1 inhibition induced by 2.5 μM ZnPPIX did not affect BTZ-Fig. 4. Pro-apoptotic effect of BTZ is increased by treatment with HO-1 inhibitor ZnPPIX only
in HTLA-230 cells. HTLA-230 and SH-SY5Y cells were co-treated with 2.5 μM ZnPPIX and
10 nM BTZ for 24 h and the apoptotic rate was assessed by AnnexinV/PI staining followed
by FACS analysis. The graphs show the mean values of three independent experiments
(means ± SE). *p b 0.05 vs respective untreated cells; § p b 0.05 vs BTZ-treated cells.dependent p53 down-regulation in HTLA-230 cells, and it had no effect
on p53 over-expression induced by 10 nM BTZ in SH-SY5Y cells
(Fig. 5B).
3.6. Effect of HO-1 inhibition on p21 expression in BTZ-treated cells
RT-PCR analysis of p21 mRNA expression revealed a marked increase
(+120%vs control) in SH-SY5Y, already at theminimumdoseused,with-
out further increase at the higher doses. Moreover, HTLA-230 cells
showed an increase of p21 mRNA of about 100% at 10 nM and up to
120% at 40 nM BTZ (Fig. 6A). The analysis of p21 protein level by WB
showed a similar trend in both cell lines treated with BTZ (+70% vs con-
trol, already at 5 nM BTZ, with no further increases in SH-SY5Y cells
and +50% vs control at 10–20–40 nM BTZ in HTLA-230 cells) (Fig. 6B).
However, in neither HTLA-230 nor SH-SY5Y cells, the co-treatment
with HO-1 inhibitor 2.5 μM ZnPPIX was able to signiﬁcantly affect p21
mRNA or protein over-expression induced by 10 nM BTZ (Fig. 6C
and D).
3.7. Effect of HO-1 inhibition onMYCN expression in BTZ-treated HTLA-230
cells
SinceMYCN ampliﬁcation is one of themost important factors relat-
ed to neuroblastoma aggressiveness and resistance to therapy, then we
veriﬁed if BTZ treatment and HO-1 inhibition were able to inﬂuence
MYCN expression. However, the expression of MYCN in SH-SY5Y cells
was below the detection limits with our experimental approach and
we only considered the analysis of HTLA-230 cells. Our results showed
that BTZ treatment was able to reduce, in a dose-dependent way, the
level of MYCNmRNA up to 35% at 40 nMBTZ in comparison to untreat-
ed cells (Fig. 7A).Moreover, theWB analysis showed thatMYCNprotein
level decreased by 25% and 30% only at the highest BTZ doses used (20
and 40 nM respectively, Fig. 7B). However, HO-1 inhibition induced by
2.5 μMZnPPIX had no effect on preventing the decrease ofMYCNmRNA
induced by BTZ (Fig. 7C). No signiﬁcative changes ofMYCN protein level
were observed in cells treated with 10 nM BTZ or co-treated with
2.5 μM ZnPPIX (Fig. 7D).
4. Discussion
Our study identiﬁes a crucial role of HO-1 up-regulation in high-risk
neuroblastoma resistance to proteasome inhibitor-based therapy. We
show that both HTLA-230 (MYCN ampliﬁed) and SH-SY5Y (MYCN
non-ampliﬁed) cell lines are sensitive to the cytostatic effect of
bortezomib, in line with the well-known ability of proteasome inhibi-
tion to reduce cell proliferation [25,26]. However, on the basis of the re-
sults obtained by MTT assay (cell number) and by the cytoﬂuorimetric
detection of apoptotic cells,we demonstrate that HTLA-230 are less sen-
sitive to BTZ treatment than SH-SY5Y cells.
BTZ has already been proposed as a useful therapeutic approach to
overcome chemoresistance and it has been approved as an anticancer
drug both alone, for the treatment of multiple myeloma [27,28], and
in combination with conventional therapies, as a chemosensitizer
[29–31]. Furthermore, the efﬁcacy of bortezomib treatment on neuro-
blastoma has already been proposed [32,33] but the molecular mecha-
nism of BTZ action is not yet fully understood. In addition, more
recently it has been pointed out that the role of BTZ as a general
chemo-sensitizer needs to be reconsidered since its efﬁcacy in a com-
bined therapy is dependent on cell type and drug used. Indeed, it has
been observed both a sensitizing effect of BTZ in combination with
radio-therapy [34] or doxorubicin [35] and an antagonistic effect in
combination with microtubule interfering-drugs [36].
In this context, we hypothesize that the efﬁcacy of BTZ could be limit-
ed by the induction of the antioxidant Nrf2-dependent cell response, fre-
quently activated in tumor cells after chemotherapy [37–39]. In fact, BTZ
treatment is able to decrease the expression level of Keap-1, the cytosolic
Fig. 5. p53 expression level is differently modulated in SH-SY5Y and HTLA-230 cells treated with BTZ and HO-1 inhibition does not interfere. (A)Western blot was performed on total protein
extract after 24 h cell exposure to increasing concentrations of BTZ (5–40 nM), checking tubulin expression as loading control. The bar graphs show themean values of three independent ex-
periments (means ± SE); * p b 0.05 and **p b 0.01 vs untreated cells. (B) p53 level was analyzed byWB on protein lysates from cells co-treated with 2.5 μM ZnPPIX and 10 nM BTZ. Lanes:
1 = control; 2 = 10 nM BTZ; 3 = 2.5 μM ZnPPIX; 4 = 2.5 μM ZnPPIX + 10 nM BTZ. All the blots reported are from one representative experiment of three. *p b 0.05 vs control.
619A.L. Furfaro et al. / Biochimica et Biophysica Acta 1842 (2014) 613–622inhibitor of Nrf2, thus increasing the total amount of Nrf2 in both cell
lines. This is due to the particular regulation of Nrf2 by proteasome. It
has been shown in other papers [40,41], indeed, that the inhibition of
26S proteasome induces a quick oxidation of Keap-1 and results in its
degradation by 20S proteasome, allowing the Nrf2 translocation into the
nucleus. However, in HTLA-230 cells, treated with BTZ, the nuclear Nrf2
level is increased, as is the ability of the nuclear proteins to bind the
DNA ARE sequence. On the contrary, in BTZ-treated SH-SY5Y cells, the
slight increase in the total Nrf2 level is not accompanied by its nuclear
translocation or by the enhancement of the DNA binding activity. Nrf2
translocation to the nucleus is a complex event and is regulated by differ-
ent post-transcriptionalmodiﬁcations that have been demonstrated to be
crucial in Nrf2 nuclear shuttling failure [42,43].
Moreover, analyzing the most important Nrf2-dependent genes, we
show the induction of only two target genes, x-CT and HO-1. Inparticular, we focus on HO-1 which results up-regulated by about 2.5
fold at the lowest doses of BTZ in SH-SY5Y and it is strongly induced
up to 20 fold at 20 nM BTZ in HTLA-230 cells. Since HO-1 transcription
is regulated not only byNrf2 but also by AP-1 andNF-κB [44], we cannot
exclude that in our cell model, especially as far as SH-SY5Y is concerned,
the up-regulation of HO-1 observed at 5–10 nMBTZ could be due to the
activation of Nrf2-independent pathways.
It is known that the induction of HO-1 exerts a strong antioxidant
and antiapoptotic effect as shown in acute myeloid leukemia resistance
to TNFα [45] and in the resistance of pancreatic tumors to gemcitabine
[17]. In order to demonstrate the implications of HO-1 in cell resistance
to BTZ cytotoxic effect, we co-treated both cell lineswith 2.5 μMZnPPIX,
an inhibitor of HO-1 activity, and 10 nM BTZ, the lowest dose able to
affect both cell viability and proliferation rate. The co-treatment is able
to strongly increase the apoptotic rate of HTLA-230 cells, conﬁrming
Fig. 6. p21 expression is induced by BTZ treatment in both cell lines and it is not prevented by HO-1 inhibition. (A) RT-PCR analysis of p21 was performed on total RNA extract from cells
after 24 h exposure to increasing concentrations of BTZ (5–40 nM). (B) Western blot was performed on total protein extract after 24 h cell exposure to increasing concentrations of BTZ
(5–40 nM), checking tubulin expression as loading control. p21mRNA expression (C) and protein level (D) was checked on cells co-treated with 2.5 μM ZnPPIX and 10 nM BTZ for 24 h.
Lanes: 1 = control; 2 = 10 nMBTZ; 3 = 2.5 μMZnPPIX; 4 = 2.5 μMZnPPIX + 10 nMBTZ. All bands shown are representative of three independent experiments. The bar graphs show
the mean values of three independent experiments (means ± SE); * p b 0.05 vs untreated cells; ** p b 0.01 vs untreated.
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same co-treatment is not able to increase the apoptotic rate of SH-
SY5Y cells, according to the slight increase of HO-1 expression induced
by BTZ.
In order to investigate the molecular pathways that could bemodu-
lated by HO-1 and involved in the resistance to bortezomib, we studied
the expression of p21, p53 and MYCN.
Here,we show that BTZ is able to induce p21 in both cell lines, to up-
regulate p53 in SH-SY5Y and down-regulate it in HTLA-230 cells, and to
decrease MYCN expression in HTLA-230 cells.
The proteasome-dependent regulation of p21 is well known [46]
and its induction correlates with cell cycle slowdown observed in BTZ-
treated cells. Although the involvement of HO-1-derived carbon mon-
oxide in p21 up-regulation has already been conﬁrmed [47], in our
study we failed to demonstrate HO-1's involvement in BTZ-induced
p21 up-regulation in both cell lines, underlining the direct involvement
of 26S proteasome activity in p21 expression.
Conversely, it should be kept in mind that p53 can be degraded, not
only by 26S proteasome [48], but also by 20S proteasome [49] and by acalpain-dependent cytosolic pathway [50]. In fact, we cannot exclude
that the treatment of HTLA-230 with bortezomib can up-regulate
other protein-degrading systems [51] in order to maintain low levels
of p53 [49]. On the other hand, we demonstrate that SH-SY5Y cells, a
less aggressive neuroblastoma type, react to proteasome inhibition
with an expected p53 increase [48]. Interestingly, since it has been sug-
gested that HO-1-derived carbon monoxide is able to reduce p53 ex-
pression inhibiting apoptosis in vascular smooth muscle cells [52], the
high up-regulation of HO-1, induced by bortezomib in HTLA-230 cells,
could contribute to the decreasing of p53 levels with the same mecha-
nism. However, the inhibition of HO-1 activity by ZnPPIX is not able to
modulate p53 levels, showing that othermechanismsmust be responsi-
ble for regulating the bortezomib-induced p53 down-regulation in
high-risk neuroblastoma. Moreover, cell death induced by the co-
treatment is p53- and p21-independent which is in agreement with a
previous study that shows bortezomib plus fenretinide induces endo-
plasmic reticulum stress-related apoptosis [33].
Furthermore, it has been demonstrated in literature that p53 plays a
role as a negative regulator of Nrf2 [53] in that it is able to interfere with
Fig. 7. Bortezomib treatment decreasesMYCN expression in HTLA-230 cells, in a HO-1 independent way. RT-PCR analysis (A) andWB analysis (B) of MYCNwere performed onHTLA-230
cell exposed to 5–40 nM BTZ for 24 h and after co-treatment with 2.5 μM ZnPPIX and 10 nM BTZ (C and D). The bands are representative of three independent experiments. All the bar
graphs show the mean values of three independent experiments (means ± SE); * p b 0.05 vs untreated cells.
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speculate that in HTLA-230 cells the p53 decrease might favor Nrf2
binding to the DNA and HO-1 transcription. On the contrary, the loss
of the ability of Nrf2 to bind to the DNA, observed in SH-SY5Y cells,
could be related to the p53 increase induced by bortezomib.
Finally, since the up-regulation of proto-oncogene MYCN in NB cells
treated with proteasome inhibitors has been shown [54], we have in-
vestigated MYCN expression in HTLA-230, a prototype of MYCN ampli-
ﬁed NB cells. In our model, BTZ treatment induces MYCN down-
regulation that could contribute to the reduction of p53 expression,
leading to a major cell survival. In fact, it has been shown that in SHEP
Tet21N cells, in which MYCN expression can be switched on and off,
MYCN expression correlates with p53 expression and, when up-
regulated, leads to apoptosis [55]. Moreover, MYCN down-regulation
induced by BTZ seems to be independent from HO-1 since it is not
prevented by HO-1 inhibition induced by ZnPPIX.
However, it is increasingly evident from literature that MYCN regu-
lation is highly complex and regulates NB biology through a wide vari-
ety of direct or indirect target genes not only in MYCN ampliﬁed cells,
but also in non-ampliﬁed cells that express low levels of MYCN protein
[56]. Therefore, the role of MYCN in the sensitivity of neuroblastoma
cells to proteasome inhibitors deserves more investigation.5. Conclusion
Wehave provided evidence that HO-1 up-regulation, playing a strong
anti-apoptotic and pro-surviving role, characterizes the increase of resis-
tance to proteasome-inhibition based therapy in high-risk MYCN-
ampliﬁed neuroblastoma. Indeed, HO-1 inhibition, achieved using
ZnPPIX, signiﬁcantly improves the pro-apoptotic effect of the proteasome
inhibitor and this combined therapy allows the reduction in the doses of
BTZused. Thus,weproposeHO-1 as amarker of chemoresistance. The de-
tection of its over-expression could direct the therapy towards the use of
HO-1 inhibitors in order to improve the efﬁcacy of chemotherapy.
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